Replies to post #732222 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Hopeforthefuture3,

Early stage biotechs can give up too much info too soon by publishing without fully understanding what they might have uncovered. Glad they didn’t do this yet as the BCG issue has delayed their progress. Best wishes.

[dstock07734]

How many patients did the company plan to enroll originally? 60? But with 40 patients enrolled, the company can draw definitive conclusion. Did the same thing happen to the poly-iclc trial? This is something you need to emphasize instead of buying and spreading the 0 ORR bullshit.

[exwannabe]

I do recall in some of the earlier presentations by LP and or Bosch showing a case or two that did seem to have substantial tumor shrinkage

You are correct. But what he said was substantial shrinkage in some tumor. The RECIST definition of response is the sum of all lesions. The paper cited clearly showed 0 PR/CR per your cited definition.

The reason for the definition is that one wants to show systemic effect (in general). Local effects are easy to get, but often useless.

Bosh in a presentation some years back had said they were to publish a follow-up paper on direct which Imo could be quite interesting but as of yet has not happened

The study was from 10 years ago.